FAST study finds no increased risk of cardiovascular events with febuxostat as compared with allopurinol for gout
A major new study examining the relative safety of medicines for the treatment of gout will be presented at the American College of Rheumatology Convergence conference and will be published in The Lancet.
Nov 10, 2020
0
5